Refinement of an Autocidal Gravid Ovitrap for mass-manufacturing

 描述（由申请人提供）：致命诱蚊产卵器是一种常见蚊子种群监测技术的改进：将成年雌性引诱到水容器中产卵，并暴露于致命剂量的杀虫剂。Autocidal Gravid Ovitrap（AGO）在几个方面改进了这项技术。它已被修改，使其更有吸引力的妊娠埃及伊蚊。杀灭剂是一种粘合剂，因此延长了田间使用寿命，同时无需杀虫剂。该项目旨在修改当前的AGO设计，使其适合大规模生产。我们的目标是生产一种有效的，具有成本效益的，持久的 前长期目标包括优化AGO的使用，以控制携带虫媒病毒的蚊子，防止登革热和其他疾病的爆发，并将该技术推广用于其他容器繁殖的蚊子物种。最终的结果预计将是一个商业上可行的产品，供专业和家庭使用。第一阶段的努力最终在原型注射模具的AGO，与个别元素的设计验证数字和竞争笼生物测定。多种合成引诱剂进行了评估，与几个执行至少以及标准干草输液。一期AGO适合大规模生产，性价比高，用户友好，对Ae有很高的吸引力。埃及人。第二阶段将产生一种可以大规模生产的产品，该产品对容器繁殖的蚊子具有有效性。注塑AGO将在大房间和现场测试的有效性和耐用性进行评估。该引诱剂配方将在竞技场和田间试验中精制，以至少与干草浸渍液一样具有吸引力，并且易于包装和运输。将扩大大规模的城市实地测试，以测试AGO在抑制Ae。aegypti和Ae.白纹伊蚊疾病预防控制中心开发的诊断“快速测试”将用于确定被困蚊子的疾病频率，以评估大规模部署AGO是否将蚊子数量减少到登革热传播阈值以下。容器繁殖的蚊子，如Ae。aegypti和Ae.白纹伊蚊是白天叮咬的讨厌蚊子。它们也是包括登革热、黄热病和基孔肯雅热在内的严重病毒性疾病的传播媒介。目前，热带国家有超过25亿人面临感染登革热的风险。CDC-NCEZID的使命是检测、预防和控制人畜共患传染病。登革热和基孔肯雅热目前还不是美国居民的主要威胁，但随着蚊子传播范围的扩大，这些疾病正在蔓延。AGO将既是一种监测工具，以检查这些日益增加的入侵物种的传播，也是一种有效的控制选择，通过在整个区域范围内抑制蚊子种群，用于疫情爆发。它有望成为长期控制讨厌的蚊子，改善受影响地区人民生活质量和预防病媒传播疾病的重要工具。

 DESCRIPTION (provided by applicant): Lethal ovitraps are a modification of a common mosquito population monitoring technology: adult females are enticed to a water container to lay their eggs and are exposed to a lethal dose of pesticide. The Autocidal Gravid Ovitrap (AGO) improves this technology in several ways. It has been modified to make it more attractive to gravid Aedes aegypti. The killing agent is an adhesive, thus extending the useful field life while negating the need for insecticides. This project aims to modify the current AGO design to make it suitable for mass production. The goal is to produce an efficacious, cost-effective, and durable AGO. Long-term objectives include optimizing use of the AGO for control of arbovirus-vectoring mosquitoes to prevent outbreaks of dengue and other diseases, and extending the technology for use with other container-breeding species of mosquitoes. The final result is expected to be a commercially viable product for professional and home use. Phase I efforts culminated in a prototype injection mold for the AGO, with individual elements of the design validated both digitally and in competitive cage bioassays. Multiple synthetic attractants were evaluated, with several performing at least as well as the standard hay infusion. The Phase I AGO is suitable for mass production, cost-effective, user-friendly, and has high attraction to Ae. aegypti. Phase II will result in a product that can be mass-manufactured with demonstrated efficacy against container- breeding mosquitoes. The injection-molded AGO will be evaluated in large room and field tests for effectiveness and durability. The attractant formulation will be refined in arena ad field tests to be at least as attractive as hay infusion, and easily packaged and shipped. Large-scale urban field testing will be expanded to test the AGO's efficacy in suppressing both Ae. aegypti and Ae. albopictus. A CDC-developed diagnostic "quick test" will be used to determine disease frequency in trapped mosquitoes, to assess if large-scale deployment of the AGO reduces the mosquito population below the dengue transmission threshold. Container-breeding mosquitoes such as Ae. aegypti and Ae. albopictus are day-biting nuisance mosquitoes. They are also vectors of serious viral diseases, including dengue fever, yellow fever, and chikungunya. Currently >2.5 billion people in tropical countries are at risk of infection with dengue fever. The mission of the CDC-NCEZID is to detect, prevent, and control zoonotic infectious diseases. Dengue fever and chikungunya are not currently major threats to US residents, but these diseases are spreading as their mosquito vectors expand their ranges. The AGO will be both a monitoring tool to check the spread of these increasingly invasive species, and an effective control option for use in outbreaks by creating area-wide suppression of mosquito populations. It promises to be an important tool in the long term battle to control nuisance mosquitoes, improve quality of life for people in affected areas, and prevent vector-borne diseases.